Telix PharmaceuticalsTLX +5.95%50 PS Ratio is 4.54 as of Jun. 29, 2026, which is 95% below its 10-year median of 86.67. GuruFocus rates TLX with a GF Score™ of 50/100 and a GF Value™ of $29.73 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 935 Biotechnology companies, Telix Pharmaceuticals ranks better than 71.12% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Telix Pharmaceuticals's share price is $11.30.
Telix Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $2.49. Hence, Telix Pharmaceuticals's PS Ratio for today is 4.54.
The historical rank and industry rank for Telix Pharmaceuticals's PS Ratio or its related term are showing as below:
TLX'
s PS Ratio Range Over the Past 10 Years
Min: 2.34 Med: 86.67 Max: 1850
Current: 4.28
During the past 11 years, Telix Pharmaceuticals's highest PS Ratio was 1850.00. The lowest was 2.34. And the median was 86.67.
TLX's PS Ratio is ranked better than 71.12% of 935
companies
in the Biotechnology industry
Industry Median: 9.29
vs TLX: 4.28
Telix Pharmaceuticals Ltd revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Telix Pharmaceuticals was 58.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 93.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 232.80% per year.
During the past 11 years, Telix Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 408.20% per year. The lowest was 93.00% per year. And the median was 226.10% per year.
Back to Basics: PS Ratio
Telix Pharmaceuticals (NAS:TLX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Telix Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telix Pharmaceuticals PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where Telix Pharmaceuticals's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Telix Pharmaceuticals's Share Price of today is $11.30.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Telix Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $2.49.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Telix Pharmaceuticals (TLX) has a PS Ratio of 4.54 as of Jun. 29, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Telix Pharmaceuticals and its competitors. This is 95% below median its historical median of 86.67. Over the past decade, Telix Pharmaceuticals' PS Ratio has ranged from 2.34 to 1,850.00. According to the industry distribution chart, Telix Pharmaceuticals ranks #270 out of 935 companies in the Biotechnology industry, placing it in the top 28.9%.
Is Telix Pharmaceuticals' PS Ratio too high?
Telix Pharmaceuticals' current PS Ratio of 4.54 is 95% below median its 10-year median of 86.67. Over the past 10 years, this metric has ranged from a low of 2.34 to a high of 1,850.00. The Biotechnology industry median PS Ratio is 9.29. Telix Pharmaceuticals' value of 4.54 is 51.1% below this industry median. Based on the distribution chart, Telix Pharmaceuticals ranks #270 out of 935 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Telix Pharmaceuticals has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telix Pharmaceuticals ranks #270 out of 935 companies for PS Ratio. This puts Telix Pharmaceuticals in the upper half of its industry. The industry median PS Ratio is 9.29. Telix Pharmaceuticals' value of 4.54 is 51.1% below this benchmark. Historically, Telix Pharmaceuticals' own PS Ratio has ranged from 2.34 to 1,850.00 over the past decade. While the company's 10-year median is 86.67 vs. the industry median of 9.29, Telix Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.29, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Telix Pharmaceuticals's current PS Ratio of 4.54 is 51.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Telix Pharmaceuticals and its competitors. For the Biotechnology industry, the median PS Ratio is 9.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telix Pharmaceuticals's current PS Ratio is 4.54, which is 95% below median its own 10-year median of 86.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (TLX) is currently considered Possible Value Trap. The stock's GF Value™ is $29.73, compared to a current price of $11.30 — trading 62% below its estimated fair value. The current PS Ratio is 4.54, which is 95% below median its 10-year median of 86.67 and 51.1% below the Biotechnology industry median of 9.29. Telix Pharmaceuticals' overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Telix Pharmaceuticals (TLX), the current PS Ratio is 4.54 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telix Pharmaceuticals (TLX) Overvalued in 2026?
Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued.
The current stock price of $11.30 is trading 62% below its estimated GF Value™ of $29.73.
GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.
Key valuation signals for TLX:
PS Ratio: 4.54 (95% below median its 10-year median of 86.67)
GF Value™: $29.73 vs. price of $11.30 (62% below fair value)
Industry Position: 51.1% below the Biotechnology median (#270 of 935)
No single metric tells the full story. See the TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
50GF Score
Get the complete analysis for TLX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLX has been successfully added to your 
